Cargando…

Expression and Clinical Significance of MDM2 in Non-Functioning PitNETs

Background and Objective: Non-functioning pituitary neuroendocrine tumors (NF-PitNETs) represent a heterogeneous tumor type that lacks effective medical treatment. MDM2, the main negative regulator of p53, binds to and forms a stable complex with p53 to regulate its activity. In this study, we measu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Xiaohui, Liu, Qian, Zhao, Sida, Cheng, Rui, Liu, Chunhui, Zhang, Gangli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9963423/ https://www.ncbi.nlm.nih.gov/pubmed/36837574 http://dx.doi.org/10.3390/medicina59020373

Ejemplares similares

Differentiation of silent corticotroph pituitary neuroendocrine tumors (PitNETs) from non-functioning PitNETs using kinetic analysis of dynamic MRI
por: Amano, Taishi, et al.
Publicado: (2023)

Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation — High-Grade PitNET or PitNEC?
por: Saeger, Wolfgang, et al.
Publicado: (2021)

Expression and methylation status of LAMA2 are associated with the invasiveness of nonfunctioning PitNET
por: Wang, Ruo-Qiang, et al.
Publicado: (2019)

How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020
por: Trouillas, Jacqueline, et al.
Publicado: (2020)

Pituitary Apoplexy in Patients with Pituitary Neuroendocrine Tumors (PitNET)
por: Gheorghe, Ana-Maria, et al.
Publicado: (2023)

PitNETs and the gut microbiota: potential connections, future directions
por: Nie, Ding, et al.
Publicado: (2023)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art
por: Feola, Tiziana, et al.
Publicado: (2022)

The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations
por: Dumitriu-Stan, Roxana-Ioana, et al.
Publicado: (2023)

Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNET
por: Zhang, Qilin, et al.
Publicado: (2023)

PMON104 Sellar Gangliocytoma-Pituitary Neuroendocrine Tumor (PitNET) Presenting As Acromegaly
por: Aurora, John, et al.
Publicado: (2022)

Touch imprint cytology is useful for the intraoperative pathological diagnosis of PitNETs’ surgical margins
por: Tanabe, Noriaki, et al.
Publicado: (2023)

FRI370 Hyperthyroidism And Acromegaly In A Patient With A Mature Plurihormonal PIT1 Lineage PitNET/Adenoma
por: Slack, Daniel, et al.
Publicado: (2023)

Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways
por: Serioli, Simona, et al.
Publicado: (2023)

Endoscopic Endonasal Transplanum–Transtuberculum Approach for Pituitary Adenomas/PitNET: 25 Years of Experience
por: Carretta, Alessandro, et al.
Publicado: (2023)

Lactotroph PitNET/adenoma associated to granulomatous hypophysitis in a patient with Crohn's disease: A case report
por: Pietrantoni, Alberto, et al.
Publicado: (2022)

P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs
por: Treppiedi, Donatella, et al.
Publicado: (2022)

Granulomatous mastitis (GM) in a young woman with a previous history of prolactin-secreting PitNET and actual normal prolactinemia
por: Boldrini, Cristiana
Publicado: (2022)

Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma
por: Tsukamoto, Taro, et al.
Publicado: (2023)

Fluorescence-guided detection of pituitary neuroendocrine tumor (PitNET) tissue during endoscopic transsphenoidal surgery available agents, their potential, and technical aspects
por: Vergeer, Rob A, et al.
Publicado: (2022)

THU099 The Challenging Management Of Silent Corticotroph PitNET—From Very Aggressive To Mild Course Of Disease During Long Follow Up
por: Bogusławska, Anna, et al.
Publicado: (2023)

Correction to: Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma
por: Tsukamoto, Taro, et al.
Publicado: (2023)

Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 2. Neoplasms other than PitNET and tumor-mimicking lesions
por: Tsukamoto, Taro, et al.
Publicado: (2023)

Correction to: Imaging of pituitary tumors: an update with the 5th WHO Classifications—part 2. Neoplasms other than PitNET and tumor-mimicking lesions
por: Tsukamoto, Taro, et al.
Publicado: (2023)

The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up
por: Ferrés, Abel, et al.
Publicado: (2022)

Detection by fluorescence of pituitary neuroendocrine tumour (PitNET) tissue during endoscopic transsphenoidal surgery using bevacizumab-800CW (DEPARTURE trial): study protocol for a non-randomised, non-blinded, single centre, feasibility and dose-finding trial
por: Vergeer, Rob A, et al.
Publicado: (2021)

SAP NetWeaver MDM 71 Administrator's Guide
por: Rao, Uda
Publicado: (2011)

Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas
por: Yao, Xiaohui, et al.
Publicado: (2017)

P53 and Murine Double Mimute 2 (MDM2) Expression Changes and Significance in Different Types of Endometrial Lesions
por: Jiang, Zhongyong, et al.
Publicado: (2016)

MDM4 Isoform Expression in Melanoma Supports an Oncogenic Role for MDM4-A
por: Alatawi, Abdullah, et al.
Publicado: (2021)

The associations between MDM4 gene polymorphisms and cancer risk
por: Wang, Ming-Jie, et al.
Publicado: (2016)

Anatomy of Mdm2 and Mdm4 in evolution
por: Tan, Ban Xiong, et al.
Publicado: (2017)

Association between MDM2 rs2279744, MDM2 rs937283, and p21 rs1801270 polymorphisms and retinoblastoma susceptibility
por: Cao, Qixin, et al.
Publicado: (2018)

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation
por: Hirose, Mitsuaki, et al.
Publicado: (2014)

A research on the protein expression of p53, p16, and MDM2 in endometriosis
por: Sang, Lin, et al.
Publicado: (2019)

The Depth-Depended Fungal Diversity and Non-depth-Depended Aroma Profiles of Pit Mud for Strong-Flavor Baijiu
por: Cai, Wenchao, et al.
Publicado: (2022)

The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells
por: Huun, Johanna, et al.
Publicado: (2017)

Mouse models of Mdm2 and Mdm4 and their clinical implications
por: Xiong, Shunbin
Publicado: (2013)

Analysis of MDM2 and MDM4 Single Nucleotide Polymorphisms, mRNA Splicing and Protein Expression in Retinoblastoma
por: McEvoy, Justina, et al.
Publicado: (2012)

Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells
por: Mrkvová, Zuzana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cldt1bfhdvc2fnbplgggk4cmoa